A randomized multi-center blinded placebo-controlled study with an open-label run-in period to evaluate the efficacy safety and pharmacokinetics of daily single subcutaneous injections of r-metHuIL-1ra [Anakinra] in polyarticular-course juvenile rheumatoid arthritis
Latest Information Update: 10 Mar 2016
At a glance
- Drugs Anakinra (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Amgen
- 01 Feb 2009 Results published in Clinical Rheumatology.
- 09 Jan 2007 Status change
- 26 Oct 2005 New trial record.